It’s been four weeks since the FDA approved the new MS drug Ocrevus (ocrelizumab). From patients to doctors to researchers, here’s what the world is saying about the approval—and what it means for the future treatment of PPMS and RRMS.
“I’m very happy I went on ocrelizumab. I love that I go every six months for ocrelizumab. I don’t have to take a pill every day or a shot.” – Pamela Arterbridge, 46, clinical trial participant
“Although, it is indeed progress that the first medication for PPMS has been approved, the patients should be fully informed of its potential risks. For patients who can obtain Rituximab, it would be safer to continue with this therapy, until with time, we are better able to advise patients about the risks associated with Ocrelizumab.” – International Multiple Sclerosis Management Practice
“It is like free advertising for Roche stock, and this is at the expense of accurately informing the American public. It’s a fake breakthrough…it’s shameless.” – Dr. Annette M. Langer-Gould, neurologist and research scientist (formerly at Genentech)
“Though I got a skin rash from my first treatment, I haven’t had other side effects. Even though I think about my MS, I have not had a relapse since I’ve been on Ocrevus.” – Wayne Donovon, 45, clinical trial participant
“Look out, Biogen and Novartis. Roche’s Ocrevus is coming for your MS sales.” – Fierce Pharma
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?